IART stock forecast, quote, news & analysis
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications... Show more
Why Integra LifeSciences (IART) Stock Is Down -20.9% in the Last 30 Days
Key Takeaways
- Integra LifeSciences shares have declined roughly 20.9% over the last 30 days, from a closing price near $15.59 to a latest available price near $12.34.
- The selloff was driven primarily by a preliminary third-quarter revenue miss and a cut to full-year 2026 guidance tied to flooding at the company's Cincinnati manufacturing facility.
- Over the last quarter, the stock has fallen approximately 35%, reflecting two distinct downdrafts around its July and October disclosures.
- Management now expects the Cincinnati site to return to full manufacturing operations in the second quarter of 2027, extending the disruption's timeline well beyond initial expectations.
- Several securities law firms have announced investigations into the company's prior disclosures, though no lawsuit had been filed at the time of reporting.
Integra LifeSciences (IART) Company Overview and Market Position
Integra LifeSciences Holdings Corporation is a global medical technology company headquartered in Princeton, New Jersey. It develops, manufactures, and sells products used in neurosurgery, surgical instrumentation, wound reconstruction, and regenerative medicine. The business is organized around two primary segments: Codman Specialty Surgical, which includes neurosurgery and surgical instruments, and Tissue Technologies, which spans wound reconstruction and regenerative tissue products.
The company serves hospitals, ambulatory surgery centers, and healthcare providers across the United States, Europe, and Asia Pacific. Its portfolio includes well-known neurosurgery brands such as DuraGen, DuraSeal, Bactiseal, and Certas Plus, alongside regenerative products including PriMatrix and DuraSorb. Investors follow the stock for its exposure to procedure-driven demand, its ongoing portfolio recovery efforts, and management's progress on operational and supply-chain execution.
Integra LifeSciences (IART) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, Integra LifeSciences shares have fallen approximately 20.9%, moving from a closing price of $15.59 on September 21, 2026, to a latest available price near $12.34. The bulk of that decline occurred on October 2, 2026, when the stock dropped 21.2% in a single session following a preliminary results release and guidance revision.
The quarterly picture is steeper. Measured from a closing price of $19.01 on July 21, 2026, the shares have lost roughly 35% through the latest session. The stock first fell sharply in late July around its second-quarter earnings report, partially recovered through much of August and September, and then re-accelerated to the downside in early October as the full scope of the Cincinnati disruption became clear.
What Drove IART Stock Price in the Last 30 Days
The dominant catalyst in the last 30 days was Integra's October 2, 2026 announcement of preliminary third-quarter results. The company projected quarterly revenue of $410 million to $412 million, below the consensus estimate of approximately $416.3 million. More significantly, management lowered full-year 2026 revenue guidance to a range of $1.634 billion to $1.654 billion, down from a prior range of $1.654 billion to $1.695 billion, and reduced adjusted earnings guidance to $2.30 to $2.40 per share from $2.40 to $2.50.
Integra attributed the shortfall to July 2026 flooding at its Cincinnati facility, which damaged equipment, inventory, and other assets. The company estimated the disruption reduced third-quarter revenue by roughly $7 million and would reduce fourth-quarter revenue by $15 million to $20 million, with full manufacturing operations not expected to resume until the second quarter of 2027.
The disclosure contrasted with earlier messaging, when management had indicated during the second-quarter earnings call that it did not expect the event to have a material impact on 2026 revenue or EPS guidance. Following the news, BMO Capital lowered its price target on the stock to $15 from $18 while maintaining a Market Perform rating, and several securities law firms announced investigations into the company's prior statements. The company also announced a proposed $600 million senior secured term loan as part of a broader refinancing effort.
What Drove IART Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of repeated downward revisions. In late July 2026, Integra reported second-quarter results that swung to a net profit from a large prior-year loss, but the company trimmed its full-year revenue outlook, citing foreign-exchange headwinds from a stronger U.S. dollar. The stock fell sharply around that report, and the July flooding at the Cincinnati site was initially characterized as a manageable disruption.
That characterization proved optimistic. When preliminary third-quarter results in early October revealed the flooding's deeper financial impact and pushed the recovery timeline into 2027, the market reassessed the stock. The combination of guidance cuts, an extended supply disruption, and a new refinancing plan weighed on investor sentiment across the quarter, keeping the shares near multi-month lows even as third-quarter results later showed modest year-over-year revenue growth.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. While Tickeron offers hundreds of bots that collectively trade thousands of tickers, only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-horizon trend models. For traders tracking names such as Integra LifeSciences, the page provides a way to monitor how automated strategies are positioning across changing market conditions. Explore the Trending AI Robots page to review current top performers and evaluate whether a systematic approach aligns with your own trading framework.
IART Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring Integra LifeSciences should focus on the pace of the Cincinnati facility's recovery and whether the company can meet its revised fourth-quarter and full-year guidance. Management's fourth-quarter revenue outlook of $413 million to $433 million sits below consensus expectations, and any additional supply disruptions could pressure results further. The timing and magnitude of insurance recoveries tied to business interruption will also influence adjusted earnings.
Beyond the flooding, watch for progress in the Tissue Technologies segment, where wound reconstruction and the planned relaunch of the SurgiMend product line are expected to contribute to growth in 2027. The resolution of the announced securities investigations, changes to analyst ratings and price targets, and the terms of the company's refinancing are additional factors that may shape sentiment. As always, these are forward-looking considerations rather than predictions, and investors should evaluate them in the context of their own objectives and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IART in -11.97% downward trend, declining for three consecutive days on October 21, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IART declined for three days, in 233 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 69 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The Aroon Indicator for IART entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IART's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.883) is normal, around the industry mean (2.923). P/E Ratio (-131.556) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices, implants and biomaterials
Industry MedicalNursingServices